Property:Results during intervention
This is a property of type Text.
J
Jahangard-Rafsanjani et al. (2013): The efficacy of selenium in prevention of oral mucositis in patients undergoing hematopoietic SCT: a randomized clinical trial +
Fever above 38.3°C in 72 patients (97.3%) during neutropenia; duration of fever comparable in both selenium and placebo arm ; p=0.98 +
Jahangard-Rafsanjani et al. (2013): The efficacy of selenium in prevention of oral mucositis in patients undergoing hematopoietic SCT: a randomized clinical trial +
Onset of mucositis after transplantation comparable in both selenium and placebo arm; p=0.81 +
Jatoi et al. (2002): Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study +
Patients reporting that weight had increased by 10% at any point in the study (6-week median time):
* Significant benefit for Megestrol Acetate arm compared to Dronabinol arm (11% vs. 3%; p=0.02)
* No differences between Megestrol Acetate + Dronabinol arm (8%) and Megestrol Acetate arm (p=0.34)
Physician data:
* Megestrol Acetate arm 14%, Dronabinol arm 5% (Megestrol Acetate arm vs. Dronabinol arm p=0.009)
* Megestrol Acetate + Dronabinol arm 11% (Megestrol Acetate arm vs. Megestrol Acetate + Dronabinol arm, p=0.49) +
Jatoi et al. (2002): Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study +
Patients reporting increase in appetite at any point in the study (6-week median time):
* Significant benefit for Megestrol Acetate arm compared to Dronabinol arm (75% vs. 49%; p=0.0001)
* No differences between Megestrol Acetate + Dronabinol arm (66%) and Megestrol Acetate arm (p=0.17) +
Jatoi et al. (2002): Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study +
NA +
Jatoi et al. (2002): Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study +
Difference baseline to end of study (6-week median time):
* No differences for Uniscale; in the FAACT-AN significant advantage for Megestrol Acetate arm over Dronabinol arm (p=0.002), as well as in individual scales physical and emotional constructs; except for emotional constructs (Megestrol Acetate arm better than Megestrol Acetate + Dronabinol arm)
* No differences between Megestrol Acetate arm and Megestrol Acetate + Dronabinol arm +
Jeon et al. (2016): Effect of intravenous high dose Vitamin C on postoperative pain and morphine use after laparoscopic colectomy: A randomized controlled trial +
NA +
Jeon et al. (2016): Effect of intravenous high dose Vitamin C on postoperative pain and morphine use after laparoscopic colectomy: A randomized controlled trial +
NA +
Jeon et al. (2016): Effect of intravenous high dose Vitamin C on postoperative pain and morphine use after laparoscopic colectomy: A randomized controlled trial +
NA +
Jeon et al. (2016): Effect of intravenous high dose Vitamin C on postoperative pain and morphine use after laparoscopic colectomy: A randomized controlled trial +
? +
Johansson et al. (2021): Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial +
After a median follow-up of 3 years: no difference by treatment in disease-free survival +
Johansson et al. (2021): Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial +
Majority of participants: low levels of 25OHD (80%);
Serum levels of 25OHD sharply rose already after 4 months of supplementation in the intervention arm (Median: 33 ng/mL), compared to the placebo arm (Median: 19 ng/mL), the increase persisted with the duration of the treatment (42 ng/mL vs. 22 ng/mL after 3 years treatment)
Additionally: difference in 25OHD increase by Breslow thickness: patients with Breslow thickness below 3 mm had a doubling of 25OHD serum levels from baseline after 12 months, patients with greater thickness experienced a much lower increases in 25OHD by time +
Johnson et al. (2010): Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain +
Placebo arm with no change (0.01), THC:CBD arm and THC arm with deterioration compared to placebo arm (THC:CBD arm = 0.63 vs. placebo arm = 0.01, p=0.045; THC arm = 0.66 vs. placebo arm = 0.01, p=0.053). +
Johnson et al. (2010): Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain +
No significant differences between THC:CBD arm/THC arm and placebo arm +
Johnson et al. (2010): Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain +
No significant differences between THC:CBD arm/THC arm and placebo arm. +
Johnson et al. (2010): Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain +
Pain in the last 24h: significant advantage for THC arm over placebo arm (-3.20 vs. 0.87; p=0.048), no difference for interference pain. +
Johnson et al. (2010): Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain +
At days 14-21: Effects for reduction of "cognitive function" in THC:CBD arm and THC arm compared to placebo arm (THC:CBD arm = -5.33 vs. placebo arm = 3.68, p=0.02; THC arm = -6.77 vs. placebo arm = 3.68, p=0.01)
Worsening of "nausea and vomiting" in THC:CBD arm compared to placebo arm (THC:CBD arm = 5.13 vs. placebo arm = -3.43, p=0.02; THC arm = -3.41 vs. placebo arm = -3.43; p=1.0).
For "pain" no difference between THC:CBD arm/THC arm and placebo arm.
For "social function" significant advantage for THC arm over placebo arm (9.66 vs. 1.58; p=0.038). +
Johnson et al. (2010): Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain +
Significant advantage for THC:CBD arm compared to placebo arm after 14-20 days (mean improvement = -1.37 vs. -0.69; p=0.014), no significant difference between THC arm and placebo arm after 14-20 days (mean improvement = -1.01 vs. -0.69; p=0.245)
Same results for median differences (THC:CBD arm vs. placebo arm = 0.55, p=0.024; THC arm vs. placebo arm = 0.24, p=0.204)
Responders:
More patients in THC:CBD arm compared to placebo arm showed improvement of more than 30% from baseline to 14-20 days (n=23 (43%) vs. n=12 (21%); Odds Ratio = 2.81; 95% CI=1.22, 6.50; p=0.006).
No difference between THC arm and placebo arm (n=12 (23%) vs. n=12 (21%); Odds Ratio 1.10 (95% CI=0.44, 2.73; p=0.28).
No data for comparison between THC:CBD arm and THC arm. +
Johnson et al. (2010): Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain +
Background medication opioids baseline to 14-21 days (median to baseline 271mg daily morphine equivalents): no significant changes in dosage
Breakthrough pain and corresponding opioid use at 14-21 days:
No difference between arms for number of days used (THC:CBD arm vs. placebo arm, p=0.697; THC arm vs. placebo arm, p=0.555); non-significant reduction in each arm (THC:CBD arm = -0.19 vs. THC arm = -0.14; placebo arm = -0.15) with no difference between arms (THC:CBD arm vs. placebo arm, p=0.688; THC arm vs. placebo arm; p=0.899); more patients in placebo arm (n=7) with increased dosage compared to THC:CBD arm (p=0.004) +
Johnson et al. (2010): Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain +
Placebo arm with improvement, THC:CBD arm and THC arm with deterioration (placebo arm = -0.35 vs. THC:CBD arm = 0.33, p=0.021; placebo arm = -0.35 vs. THC arm = 0.29, p=0.028) +